{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:28:49Z","timestamp":1792877329092,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"crossref","award":["Anniversary Fund, 15346"],"award-info":[{"award-number":["Anniversary Fund, 15346"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Fungal Infect Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12281-019-00342-w","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T06:52:57Z","timestamp":1561013577000},"page":"129-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["(New) Methods for Detection of Aspergillus fumigatus Resistance in Clinical Samples"],"prefix":"10.1007","volume":"13","author":[{"given":"Jeffrey D.","family":"Jenks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Buchheidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"11","key":"342_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/myc.12836","volume":"61","author":"M Hoenigl","year":"2018","unstructured":"\u2022\u2022 Hoenigl M, Gangneux JP, Segal E, Alanio A, Chakrabarti A, Chen SC, et al. Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together. Mycoses. 2018;61(11):885\u201394. \n                      https:\/\/doi.org\/10.1111\/myc.12836\n                      \n                    \n                              Describes global guidelines and optimal collaboration strategies to optimize clinical care in resource-rich and resource-limited settings.","journal-title":"Mycoses"},{"issue":"3","key":"342_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/myc.12881","volume":"62","author":"JD Jenks","year":"2019","unstructured":"\u2022\u2022 Jenks JD, Mehta SR, Taplitz R, Aslam S, Reed SL, Hoenigl M. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test in bronchoalveolar lavage. Mycoses. 2019;62(3):230\u20136. \n                      https:\/\/doi.org\/10.1111\/myc.12881\n                      \n                    \n                              Paper highlights the difficulties of defining, categorizing, and diagnosing Invasive aspergillosis in non-neutropenic hosts.","journal-title":"Mycoses"},{"key":"342_CR3","doi-asserted-by":"publisher","unstructured":"Cornely OA, Lass-Florl C, Lagrou K, Arsic-Arsenijevic V, Hoenigl M. Improving outcome of fungal diseases - guiding experts and patients towards excellence. Mycoses. 2017. \n                      https:\/\/doi.org\/10.1111\/myc.12628\n                      \n                    .","DOI":"10.1111\/myc.12628"},{"issue":"3","key":"342_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jinf.2018.05.001","volume":"77","author":"S Heldt","year":"2018","unstructured":"Heldt S, Prattes J, Eigl S, Spiess B, Flick H, Rabensteiner J, et al. Diagnosis of invasive aspergillosis in hematological malignancy patients: performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect. 2018;77(3):235\u201341. \n                      https:\/\/doi.org\/10.1016\/j.jinf.2018.05.001\n                      \n                    .","journal-title":"J Infect"},{"issue":"2","key":"342_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jinf.2018.09.006","volume":"78","author":"M Hoenigl","year":"2019","unstructured":"\u2022 Hoenigl M, Orasch T, Faserl K, Prattes J, Loeffler J, Springer J, et al. Triacetylfusarinine C: a urine biomarker for diagnosis of invasive aspergillosis. J Infect. 2019;78(2):150\u20137. \n                      https:\/\/doi.org\/10.1016\/j.jinf.2018.09.006\n                      \n                    \n                              Important paper, as point-of-care diagnostics play a major role in critically ill patients.","journal-title":"J Infect"},{"issue":"3","key":"342_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jinf.2018.10.014","volume":"78","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Taplitz R, Law N, Reed SL, Hoenigl M. Bronchoalveolar lavage Aspergillus galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies. The Journal of infection. 2019;78(3):249\u201359. \n                      https:\/\/doi.org\/10.1016\/j.jinf.2018.10.014\n                      \n                    .","journal-title":"The Journal of infection."},{"issue":"1","key":"342_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14787210.2018.1558054","volume":"17","author":"JD Jenks","year":"2019","unstructured":"\u2022 Jenks JD, Salzer HJF, Hoenigl M. Improving the rates of Aspergillus detection: an update on current diagnostic strategies. Expert Rev Anti-Infect Ther. 2019;17(1):39\u201350. \n                      https:\/\/doi.org\/10.1080\/14787210.2018.1558054\n                      \n                    \n                              Diagnosis of fungal infections is a major issue in the treatment of immunocompromised patients. This review provides an important overview on the current status of diagnostic strategies.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"Supplement_2","key":"342_CR8","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","volume":"57","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: which drug and when? Med Mycol. 2019;57(Supplement_2):S168\u2013s78. \n                      https:\/\/doi.org\/10.1093\/mmy\/myy052\n                      \n                    .","journal-title":"Med Mycol"},{"issue":"3","key":"342_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/cid\/civ885","volume":"62","author":"PE Verweij","year":"2016","unstructured":"Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362\u20138. \n                      https:\/\/doi.org\/10.1093\/cid\/civ885\n                      \n                    .","journal-title":"Clin Infect Dis"},{"issue":"9","key":"342_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/myc.12788","volume":"61","author":"A Schauwvlieghe","year":"2018","unstructured":"\u2022\u2022 Schauwvlieghe A, de Jonge N, van Dijk K, Verweij PE, Bruggemann RJ, Biemond BJ, et al. The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. Mycoses. 2018;61(9):656\u201364. \n                      https:\/\/doi.org\/10.1111\/myc.12788\n                      \n                    \n                              This paper describes the increasing incidence of azole resistance in the Netherlands, an increasing problem globally.","journal-title":"Mycoses"},{"issue":"5","key":"342_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/mmy\/myw102","volume":"55","author":"S Eigl","year":"2017","unstructured":"Eigl S, Hoenigl M, Spiess B, Heldt S, Prattes J, Neumeister P, et al. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Med Mycol. 2017;55(5):528\u201334. \n                      https:\/\/doi.org\/10.1093\/mmy\/myw102\n                      \n                    .","journal-title":"Med Mycol"},{"key":"342_CR12","doi-asserted-by":"publisher","unstructured":"Hoenigl M. Fungal translocation: a driving force behind the occurrence of non-AIDS events? Clin Infect Dis. 2019. \n                      https:\/\/doi.org\/10.1093\/cid\/ciz215\n                      \n                    .","DOI":"10.1093\/cid\/ciz215"},{"issue":"1","key":"342_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/myc.12704","volume":"61","author":"M Hoenigl","year":"2018","unstructured":"Hoenigl M, Eigl S, Heldt S, Duettmann W, Thornton C, Prattes J. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Mycoses. 2018;61(1):40\u20133. \n                      https:\/\/doi.org\/10.1111\/myc.12704\n                      \n                    .","journal-title":"Mycoses"},{"key":"342_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fmicb.2018.00555","volume":"9","author":"P Postina","year":"2018","unstructured":"Postina P, Skladny J, Boch T, Cornely OA, Hamprecht A, Rath PM, et al. Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients. Front Microbiol. 2018;9:555. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.00555\n                      \n                    .","journal-title":"Front Microbiol"},{"issue":"6","key":"342_CR15","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1128\/jcm.00101-11","volume":"49","author":"PL White","year":"2011","unstructured":"White PL, Perry MD, Moody A, Follett SA, Morgan G, Barnes RA. Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive aspergillosis. J Clin Microbiol. 2011;49(6):2169\u201374. \n                      https:\/\/doi.org\/10.1128\/jcm.00101-11\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"10","key":"342_CR16","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1128\/jcm.01135-14","volume":"52","author":"PL White","year":"2014","unstructured":"White PL, Hibbitts SJ, Perry MD, Green J, Stirling E, Woodford L, et al. Evaluation of a commercially developed semiautomated PCR-surface-enhanced Raman scattering assay for diagnosis of invasive fungal disease. J Clin Microbiol. 2014;52(10):3536\u201343. \n                      https:\/\/doi.org\/10.1128\/jcm.01135-14\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"12","key":"342_CR17","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1128\/jcm.05026-11","volume":"49","author":"R Torelli","year":"2011","unstructured":"Torelli R, Sanguinetti M, Moody A, Pagano L, Caira M, De Carolis E, et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol. 2011;49(12):4273\u20138. \n                      https:\/\/doi.org\/10.1128\/jcm.05026-11\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"3","key":"342_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1128\/jcm.03216-14","volume":"53","author":"GL Chong","year":"2015","unstructured":"Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol. 2015;53(3):868\u201374. \n                      https:\/\/doi.org\/10.1128\/jcm.03216-14\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"12","key":"342_CR19","doi-asserted-by":"publisher","first-page":"O1059","DOI":"10.1111\/1469-0691.12749","volume":"20","author":"A Huttner","year":"2014","unstructured":"Huttner A, Emonet S, Harbarth S, Renzi G, Kaiser L, Schrenzel J. Polymerase-chain reaction\/electrospray ionization-mass spectrometry for the detection of bacteria and fungi in bronchoalveolar lavage fluids: a prospective observational study. Clin Microbiol Infect. 2014;20(12):O1059\u201366. \n                      https:\/\/doi.org\/10.1111\/1469-0691.12749\n                      \n                    .","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"342_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/jac\/dkq041","volume":"65","author":"CH Klaassen","year":"2010","unstructured":"Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother. 2010;65(5):901\u20135. \n                      https:\/\/doi.org\/10.1093\/jac\/dkq041\n                      \n                    .","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"342_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJMc061720","volume":"356","author":"PE Verweij","year":"2007","unstructured":"Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356(14):1481\u20133. \n                      https:\/\/doi.org\/10.1056\/NEJMc061720\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"8","key":"342_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/ps.4029","volume":"71","author":"CL Price","year":"2015","unstructured":"Price CL, Parker JE, Warrilow AG, Kelly DE, Kelly SL. Azole fungicides - understanding resistance mechanisms in agricultural fungal pathogens. Pest Manag Sci. 2015;71(8):1054\u20138. \n                      https:\/\/doi.org\/10.1002\/ps.4029\n                      \n                    .","journal-title":"Pest Manag Sci"},{"issue":"34","key":"342_CR23","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1021\/acs.jafc.5b02728","volume":"63","author":"MM Azevedo","year":"2015","unstructured":"Azevedo MM, Faria-Ramos I, Cruz LC, Pina-Vaz C, Rodrigues AG. Genesis of azole antifungal resistance from agriculture to clinical settings. J Agric Food Chem. 2015;63(34):7463\u20138. \n                      https:\/\/doi.org\/10.1021\/acs.jafc.5b02728\n                      \n                    .","journal-title":"J Agric Food Chem"},{"key":"342_CR24","doi-asserted-by":"publisher","unstructured":"Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, et al. In vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories. Antimicrob Agents Chemother. 2018;62(10). \n                      https:\/\/doi.org\/10.1128\/aac.01230-18\n                      \n                    .","DOI":"10.1128\/aac.01230-18"},{"key":"342_CR25","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3389\/fmicb.2018.01656","volume":"9","author":"E Pinto","year":"2018","unstructured":"Pinto E, Monteiro C, Maia M, Faria MA, Lopes V, Lameiras C, et al. Aspergillus species and antifungals susceptibility in clinical setting in the north of Portugal: cryptic species and emerging azoles resistance in A. fumigatus. Front Microbiol. 2018;9:1656. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.01656\n                      \n                    .","journal-title":"Front Microbiol"},{"issue":"1","key":"342_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jac\/dkx354","volume":"73","author":"JB Buil","year":"2018","unstructured":"Buil JB, Bruggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, et al. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. J Antimicrob Chemother. 2018;73(1):134\u201342. \n                      https:\/\/doi.org\/10.1093\/jac\/dkx354\n                      \n                    .","journal-title":"J Antimicrob Chemother"},{"key":"342_CR27","volume-title":"CLSI document M38","author":"Institute. CaLS","year":"2017","unstructured":"Institute. CaLS. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi.; Approved standard. In: CLSI document M38. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.","edition":"3"},{"issue":"10","key":"342_CR28","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1128\/jcm.01187-06","volume":"44","author":"A Espinel-Ingroff","year":"2006","unstructured":"Espinel-Ingroff A. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol. 2006;44(10):3616\u201322. \n                      https:\/\/doi.org\/10.1128\/jcm.01187-06\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"3","key":"342_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/dkg384","volume":"52","author":"E Martin-Mazuelos","year":"2003","unstructured":"Martin-Mazuelos E, Peman J, Valverde A, Chaves M, Serrano MC, Canton E. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother. 2003;52(3):365\u201370. \n                      https:\/\/doi.org\/10.1093\/jac\/dkg384\n                      \n                    .","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"342_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0732-8893(02)00544-8","volume":"45","author":"MA Pfaller","year":"2003","unstructured":"Pfaller MA, Messer SA, Boyken L, Hollis RJ, Diekema DJ. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis. 2003;45(4):241\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"342_CR31","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1128\/aac.00862-09","volume":"53","author":"R Araujo","year":"2009","unstructured":"Araujo R, Espinel-Ingroff A. Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. Antimicrob Agents Chemother. 2009;53(11):4921\u20133. \n                      https:\/\/doi.org\/10.1128\/aac.00862-09\n                      \n                    .","journal-title":"Antimicrob Agents Chemother"},{"key":"342_CR32","doi-asserted-by":"publisher","unstructured":"Arendrup MC, Verweij P, Nielsen HV. Evaluation of MIC strip isavuconazole test for susceptibility testing of wild-type and non-wild-type Aspergillus fumigatus isolates. Antimicrob Agents Chemother. 2017;61(1). \n                      https:\/\/doi.org\/10.1128\/aac.01659-16\n                      \n                    .","DOI":"10.1128\/aac.01659-16"},{"key":"342_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/DDDT.S145545","volume":"12","author":"JD Jenks","year":"2018","unstructured":"Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033\u201344. \n                      https:\/\/doi.org\/10.2147\/DDDT.S145545\n                      \n                    .","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"342_CR34","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1128\/JCM.40.6.2101-2107.2002","volume":"40","author":"A Espinel-Ingroff","year":"2002","unstructured":"Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol. 2002;40(6):2101\u20137.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"342_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1128\/jcm.01677-09","volume":"48","author":"J Fuller","year":"2010","unstructured":"Fuller J, Schofield A, Jiwa S, Sand C, Jansen B, Rennie R. Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration. J Clin Microbiol. 2010;48(2):479\u201382. \n                      https:\/\/doi.org\/10.1128\/jcm.01677-09\n                      \n                    .","journal-title":"J Clin Microbiol"},{"key":"342_CR36","doi-asserted-by":"publisher","unstructured":"Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E, Castro C, et al. Method-dependent epidemiological cutoff values for detection of triazole resistance in Candida and Aspergillus species for the Sensititre YeastOne colorimetric broth and Etest agar diffusion methods. Antimicrob Agents Chemother. 2019;63(1). \n                      https:\/\/doi.org\/10.1128\/aac.01651-18\n                      \n                    .","DOI":"10.1128\/aac.01651-18"},{"key":"342_CR37","doi-asserted-by":"publisher","unstructured":"Guinea J, Verweij PE, Meletiadis J, Mouton JW, Barchiesi F, Arendrup MC. How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. Clin Microbiol Infect. 2018. \n                      https:\/\/doi.org\/10.1016\/j.cmi.2018.09.008\n                      \n                    .","DOI":"10.1016\/j.cmi.2018.09.008"},{"issue":"10","key":"342_CR38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/(sici)1097-0231(19980529)12:10<630::Aid-rcm206>3.0.Co;2-0","volume":"12","author":"RJ Arnold","year":"1998","unstructured":"Arnold RJ, Reilly JP. Fingerprint matching of E. coli strains with matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry of whole cells using a modified correlation approach. Rapid Commun Mass Spectrom : RCM. 1998;12(10):630\u20136. \n                      https:\/\/doi.org\/10.1002\/(sici)1097-0231(19980529)12:10<630::Aid-rcm206>3.0.Co;2-0\n                      \n                    .","journal-title":"Rapid Commun Mass Spectrom : RCM"},{"issue":"20","key":"342_CR39","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1002\/pmic.200900152","volume":"9","author":"C Marinach","year":"2009","unstructured":"Marinach C, Alanio A, Palous M, Kwasek S, Fekkar A, Brossas JY, et al. MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole. Proteomics. 2009;9(20):4627\u201331. \n                      https:\/\/doi.org\/10.1002\/pmic.200900152\n                      \n                    .","journal-title":"Proteomics."},{"issue":"7","key":"342_CR40","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1128\/jcm.00224-12","volume":"50","author":"E De Carolis","year":"2012","unstructured":"De Carolis E, Vella A, Florio AR, Posteraro P, Perlin DS, Sanguinetti M, et al. Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species. J Clin Microbiol. 2012;50(7):2479\u201383. \n                      https:\/\/doi.org\/10.1128\/jcm.00224-12\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"7","key":"342_CR41","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1128\/jcm.00254-17","volume":"55","author":"MR Gitman","year":"2017","unstructured":"Gitman MR, McTaggart L, Spinato J, Poopalarajah R, Lister E, Husain S, et al. Antifungal susceptibility testing of Aspergillus spp. by using a composite correlation index (CCI)-based matrix-assisted laser desorption ionization-time of flight mass spectrometry method appears to not offer benefit over traditional broth microdilution testing. J Clin Microbiol. 2017;55(7):2030\u20134. \n                      https:\/\/doi.org\/10.1128\/jcm.00254-17\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"3","key":"342_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/jof1030367","volume":"1","author":"C Rizzato","year":"2015","unstructured":"Rizzato C, Lombardi L, Zoppo M, Lupetti A, Tavanti A. Pushing the limits of MALDI-TOF mass spectrometry: beyond fungal species identification. J Fungi (Basel, Switzerland). 2015;1(3):367\u201383. \n                      https:\/\/doi.org\/10.3390\/jof1030367\n                      \n                    .","journal-title":"J Fungi (Basel, Switzerland)"},{"issue":"2","key":"342_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/jcm.01640-16","volume":"55","author":"M Sanguinetti","year":"2017","unstructured":"Sanguinetti M, Posteraro B. Identification of molds by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2017;55(2):369\u201379. \n                      https:\/\/doi.org\/10.1128\/jcm.01640-16\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"7","key":"342_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103113","volume":"9","author":"B Spiess","year":"2014","unstructured":"Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, et al. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. PLoS One. 2014;9(7):e103113. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0103113\n                      \n                    .","journal-title":"PLoS One"},{"issue":"7","key":"342_CR45","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1128\/AAC.05902-11","volume":"56","author":"B Spiess","year":"2012","unstructured":"Spiess B, Seifarth W, Merker N, Howard SJ, Reinwald M, Dietz A, et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. AntimicrobAgents Chemother. 2012;56(7):3905\u201310.","journal-title":"AntimicrobAgents Chemother"},{"issue":"Suppl 5","key":"342_CR46","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1093\/cid\/ciu639","volume":"59","author":"JR Perfect","year":"2014","unstructured":"Perfect JR, Hachem R, Wingard JR. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin Infect Dis. 2014;59(Suppl 5):S352\u20135. \n                      https:\/\/doi.org\/10.1093\/cid\/ciu639\n                      \n                    .","journal-title":"Clin Infect Dis"},{"issue":"5","key":"342_CR47","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/jac\/dku566","volume":"70","author":"J Steinmann","year":"2015","unstructured":"Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015;70(5):1522\u20136. \n                      https:\/\/doi.org\/10.1093\/jac\/dku566\n                      \n                    .","journal-title":"J Antimicrob Chemother"},{"key":"342_CR48","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1093\/jac\/dkw323","volume":"71","author":"GM Chong","year":"2016","unstructured":"Chong GM, van der Beek MT, von dem Borne PA, Boelens J, Steel E, Kampinga GA, et al. PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay(R) in 201 patients with haematological disease suspected for invasive aspergillosis. J Antimicrob Chemother. 2016;71:3528\u201335. \n                      https:\/\/doi.org\/10.1093\/jac\/dkw323\n                      \n                    .","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"342_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","volume":"49","author":"P Koehler","year":"2017","unstructured":"\u2022\u2022 Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int J Antimicrob Agents. 2017;49(2):218\u201323. \n                      https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.10.019\n                      \n                    \n                              This very important study shows the clinical relevance of azole resistance in hematological patients on triazole therapy with azole-resistant\n                              A. fumigatus\n                              infections.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"342_CR50","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1128\/jcm.43.2.906-908.2005","volume":"43","author":"JP Trama","year":"2005","unstructured":"Trama JP, Mordechai E, Adelson ME. Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaconazole by real-time PCR and pyrosequencing. J Clin Microbiol. 2005;43(2):906\u20138. \n                      https:\/\/doi.org\/10.1128\/jcm.43.2.906-908.2005\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"4","key":"342_CR51","first-page":"1478","volume":"48","author":"JW van der Linden","year":"2010","unstructured":"van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. JClinMicrobiol. 2010;48(4):1478\u201380.","journal-title":"JClinMicrobiol."},{"issue":"9","key":"342_CR52","first-page":"1123","volume":"52","author":"DW Denning","year":"2011","unstructured":"Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. ClinInfectDis. 2011;52(9):1123\u20139.","journal-title":"ClinInfectDis."},{"issue":"1","key":"342_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/mmy\/myx015","volume":"56","author":"M Weber","year":"2018","unstructured":"Weber M, Schaer J, Walther G, Kaerger K, Steinmann J, Rath PM, et al. FunResDB-A web resource for genotypic susceptibility testing of Aspergillus fumigatus. Med Mycol. 2018;56(1):117\u201320. \n                      https:\/\/doi.org\/10.1093\/mmy\/myx015\n                      \n                    .","journal-title":"Med Mycol"},{"key":"342_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fmicb.2018.00740","volume":"9","author":"PM Rath","year":"2018","unstructured":"\u2022\u2022 Rath PM, Steinmann J. Overview of commercially available PCR assays for the detection of Aspergillus spp. DNA in patient samples. Front Microbiol. 2018;9:740. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.00740\n                      \n                    \n                              This paper compares the five most important commercially available molecular\n                              Aspergillus\n                              DNA and azole-resistant detection systems.","journal-title":"Front Microbiol"},{"issue":"11","key":"342_CR55","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/jac\/dkx262","volume":"72","author":"A Schauwvlieghe","year":"2017","unstructured":"Schauwvlieghe A, Vonk AG, Buddingh EP, Hoek RAS, Dalm VA, Klaassen CHW, et al. Detection of azole-susceptible and azole-resistant Aspergillus coinfection by cyp51A PCR amplicon melting curve analysis. J Antimicrob Chemother. 2017;72(11):3047\u201350. \n                      https:\/\/doi.org\/10.1093\/jac\/dkx262\n                      \n                    .","journal-title":"J Antimicrob Chemother"},{"key":"342_CR56","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1128\/jcm.00905-15","volume":"53","author":"PL White","year":"2015","unstructured":"White PL, Barnes RA, Springer J, Klingspor L, Cuenca-Estrella M, Morton CO, et al. The clinical performance of Aspergillus PCR when testing serum and plasma- a study by the European Aspergillus PCR Initiative. J Clin Microbiol. 2015;53:2832\u20137. \n                      https:\/\/doi.org\/10.1128\/jcm.00905-15\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"8","key":"342_CR57","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1128\/jcm.00411-17","volume":"55","author":"PL White","year":"2017","unstructured":"White PL, Posso RB, Barnes RA. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs directly from plasma samples. J Clin Microbiol. 2017;55(8):2356\u201366. \n                      https:\/\/doi.org\/10.1128\/jcm.00411-17\n                      \n                    .","journal-title":"J Clin Microbiol"},{"issue":"11","key":"342_CR58","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1128\/jcm.01032-17","volume":"55","author":"E Dannaoui","year":"2017","unstructured":"Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, et al. Molecular diagnosis of invasive aspergillosis and detection of azole resistance by a newly commercialized PCR kit. J Clin Microbiol. 2017;55(11):3210\u20138. \n                      https:\/\/doi.org\/10.1128\/jcm.01032-17\n                      \n                    .","journal-title":"J Clin Microbiol"},{"key":"342_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3389\/fmicb.2018.00531","volume":"9","author":"H Guegan","year":"2018","unstructured":"Guegan H, Chevrier S, Belleguic C, Deneuville E, Robert-Gangneux F, Gangneux JP. Performance of molecular approaches for Aspergillus detection and azole resistance surveillance in cystic fibrosis. Front Microbiol. 2018;9:531. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.00531\n                      \n                    .","journal-title":"Front Microbiol"},{"key":"342_CR60","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3389\/fmicb.2018.01395","volume":"9","author":"A Tsitsopoulou","year":"2018","unstructured":"Tsitsopoulou A, Posso R, Vale L, Bebb S, Johnson E, White PL. Determination of the prevalence of triazole resistance in environmental Aspergillus fumigatus strains isolated in South Wales, UK. Front Microbiol. 2018;9:1395. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.01395\n                      \n                    .","journal-title":"Front Microbiol"},{"key":"342_CR61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fmicb.2018.00516","volume":"9","author":"T Zoran","year":"2018","unstructured":"Zoran T, Sartori B, Sappl L, Aigner M, Sanchez-Reus F, Rezusta A, et al. Azole-resistance in Aspergillus terreus and related species: an emerging problem or a rare phenomenon? Front Microbiol. 2018;9:516. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.00516\n                      \n                    .","journal-title":"Front Microbiol"},{"key":"342_CR62","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3389\/fmicb.2018.00515","volume":"9","author":"JB Buil","year":"2018","unstructured":"Buil JB, Zoll J, Verweij PE, Melchers WJG. Molecular detection of azole-resistant Aspergillus fumigatus in clinical samples. Front Microbiol. 2018;9:515. \n                      https:\/\/doi.org\/10.3389\/fmicb.2018.00515\n                      \n                    .","journal-title":"Front Microbiol"}],"updated-by":[{"DOI":"10.1007\/s12281-019-00346-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000}}],"container-title":["Current Fungal Infection Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12281-019-00342-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12281-019-00342-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12281-019-00342-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T23:31:57Z","timestamp":1592523117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12281-019-00342-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s12281-019-00342-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12281-019-00346-6","asserted-by":"object"}]},"ISSN":["1936-3761","1936-377X"],"issn-type":[{"value":"1936-3761","type":"print"},{"value":"1936-377X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"20 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding information was incomplete. The correct information is given below.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The funders had no role in the study design, data collection, analysis, interpretation, decision to publish, in the writing of the manuscript, or in the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Dieter Buchheidt reports being a consultant to Basilea, Gilead Sciences, and Merck Sharp & Dohme\/Merck; receiving research grants from Gilead Sciences and Pfizer; serving on the speakers\u2019 bureau of Astellas, Basilea, Gilead Sciences, Merck Sharp & Dohme\/Merck, Pfizer, and TEVA; and receiving travel grants from Astellas, Gilead Sciences, Merck Sharp & Dohme\/Merck, and Pfizer. Martin Hoenigl reports untied research funding from Gilead. Jeffrey Jenks and Birgit Spiess declare no conflict of interest relevant to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}